Biotech stocks poised for long-term growth

What happened: Biotech stocks are poised for long-term growth, driven by a wave of potential blockbuster launches and innovative therapies. Elanco Animal Health (ELAN) is among the top healthcare stocks, with seven potential blockbusters in its pipeline. Moderna and Regeneron are also favored for their innovative technologies and promising candidates. Clinical-stage biotechs like Arvinas, Homology, and Madrigal have dense milestone calendars and strong analyst support. Biohaven, Eli Lilly, AbbVie, and Jade Biosciences are also highlighted for their long-term potential. Meanwhile, Danaher Corp. is seen as a smart bet as biotech funding trends shift.

Market impact: The biotech sector is experiencing a resurgence, with investors favoring companies with strong pipelines and cash runways. This is driving growth in the sector, with specific stocks like ELAN, BHVN, LLY, ABBV, and JBIO seeing increased analyst attention and price targets. The shift in biotech funding trends is also affecting early-stage companies, with some forced to cut spending or shut down.

What to watch next: Investors should monitor the progress of these companies' clinical trials and regulatory milestones. Key upcoming catalysts include the first-in-human dosing results for BHV-8100 (Biohaven, June 1, 2026), the Phase 3 data readout for VERVE-102 (Eli Lilly, Q4 2026), and the regulatory decisions for AbbVie's IBD pipeline (2027-2028). Additionally, the broader biotech funding trends and the performance of early-stage companies will provide insights into the sector's overall health.